0T20 Stock Chart & Stats
€6.60
€0.00(0.00%)
At close: 4:00 PM EDT
€6.60
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€6.40 - €6.60
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€7.09M
Enterprise Value€8.37
Total Cash (Recent Filing)€3.13M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.43
Next Earnings
Nov 12, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding15,368,277
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-14.78
Price to Sales (P/S)3.33
P/FCF Ratio-0.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.86Price Target Upside-86.92% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-1.23
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetThe absence of debt reduces refinancing and interest-burden risk while preserving flexibility to direct available capital toward antiviral development. This provides some financial resilience, although ongoing losses still require careful funding management.
Antiviral Pipeline And PartnershipsThe company is building a focused antiviral platform addressing Hantavirus, Ebola and potentially Lassa Fever. External collaborations, validated animal models and planned local manufacturing could support development, emergency access and strategic relevance.
Near-Term Funding RunwayThe April financing and available at-the-market program provide capital to continue clinical and regulatory work over the next several months. This lowers immediate interruption risk for development programs, though further financing may be needed afterward.
Bears Say
Persistent Operating LossesSustained negative operating and free cash flow shows that the business has not yet produced self-funding operations. Continued research spending and large cash burn increase dependence on equity or other external financing to maintain the pipeline.
Negative Shareholders' EquityNegative equity indicates accumulated losses or write-downs have overwhelmed the capital base. This weakens financial flexibility, may constrain financing choices and leaves the company more exposed to dilution while it remains pre-revenue.
Regulatory Development SetbacksRegulatory obstacles have delayed the planned influenza Phase 2a study and created uncertainty around U.S. clinical advancement. Additional toxicology work and agency responses could extend timelines, increase costs and postpone proof-of-concept data.
Traws Pharma News
0T20 FAQ
What was Traws Pharma’s price range in the past 12 months?
Traws Pharma lowest stock price was €6.40 and its highest was €6.60 in the past 12 months.
What is Traws Pharma’s market cap?
Traws Pharma’s market cap is €7.09M.
When is Traws Pharma’s upcoming earnings report date?
Traws Pharma’s upcoming earnings report date is Nov 12, 2026 which is in 55 days.
How were Traws Pharma’s earnings last quarter?
Traws Pharma released its earnings results on Aug 14, 2026. The company reported -€0.14 earnings per share for the quarter, beating the consensus estimate of -€0.292 by €0.153.
Is Traws Pharma overvalued?
According to Wall Street analysts Traws Pharma’s price is currently Overvalued.
Does Traws Pharma pay dividends?
Traws Pharma does not currently pay dividends.
What is Traws Pharma’s EPS estimate?
Traws Pharma’s EPS estimate is -0.18.
How many shares outstanding does Traws Pharma have?
Traws Pharma has 15,368,277 shares outstanding.
What happened to Traws Pharma’s price movement after its last earnings report?
Traws Pharma reported an EPS of -€0.14 in its last earnings report, beating expectations of -€0.292. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Traws Pharma?
Currently, no hedge funds are holding shares in DE:0T20
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Traws Pharma
Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through trials for pandemic influenza. Additionally, Traws Pharma's oncology portfolio features narazaciclib, a multi-kinase CDK4/6 inhibitor. This compound is presently in Phase 1/2 clinical trials in cancer patients, being evaluated both independently and in conjunction with letrozole, with the goal of establishing the recommended Phase 2 dosage for future work in endometrial cancer. The company is also investigating oral rigosertib, exploring its potential as a standalone therapy or in combination regimens across diverse cancer types. Originally established in 1998 as Onconova Therapeutics, Inc., the company officially adopted its current name, Traws Pharma, Inc., in April 2024. Its corporate headquarters are located in Newtown, Pennsylvania.
0T20 Stock 12 Month Forecast
Average Price Target
€0.86
▼(-86.92% Downside)